NCT03528226 Exercise Training and Endothelial Function in Type 1 Diabetes
| NCT ID | NCT03528226 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Lille |
| Condition | Type1diabetes |
| Study Type | INTERVENTIONAL |
| Enrollment | 34 participants |
| Start Date | 2019-11-12 |
| Primary Completion | 2028-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 34 participants in total. It began in 2019-11-12 with a primary completion date of 2028-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Endothelial dysfunction and vasoreactivity disorders are early subclinical complications of type 1 diabetes (T1D). In a preventive setting, in T1D patients still free of complications, the research of non-pharmacological interventions to improve endothelial function appears fundamental. In this randomized controlled trial, the effects of exercise training on endothelial function will be evaluated in T1D adults. Secondary objectives are to evaluate the exercise training effects on the micro and macrovascular function and exercise-induced tissue vasoreactivity and their possible neurometabolic consequences. An improvement in vascular function, particularly endothelium-dependent, as well as in neurometabolic profile, through this non-pharmacological strategy is expected
Eligibility Criteria
Inclusion Criteria: * Covered by social security * With a T1Diabete, diagnosed for at least 1 year, and free from macrovascular and microvascular diabetic complications. Exclusion Criteria: * type 1 diabetes diagnoses for less than 1 year * MODY diabetes, mitochondrial diabetes or type 2 diabetes * presence of macrovascular and/or microvascular diabetic complications (retinopathy, nephropathy, neuropathy ,…) * Obesity (Body Mass Index \> 30 kg/m² * Smokers * Hypertension * Disabling painful discomfort for trunk, upper or lower limb movements * Active chronic disease or in remission (excluding type 1 diabetes) * Head trauma in the past
Contact & Investigator
Anne Vambergue, MD,Phd
PRINCIPAL INVESTIGATOR
University Hospital, Lille
Frequently Asked Questions
Who can join the NCT03528226 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Type1diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03528226 currently recruiting?
Yes, NCT03528226 is actively recruiting participants. Contact the research team at anne.vambergue@chu-lille.fr for enrollment information.
Where is the NCT03528226 trial being conducted?
This trial is being conducted at Lille, France.
Who is sponsoring the NCT03528226 clinical trial?
NCT03528226 is sponsored by University Hospital, Lille. The principal investigator is Anne Vambergue, MD,Phd at University Hospital, Lille. The trial plans to enroll 34 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.